Released Presentations
PLENARY SESSIONS

FIRST PLENARY SESSION:
ASSIGNING REGIONAL PRIORITIES & THE USE OF HTA & ECONOMIC EVALUATIONS IN LATIN AMERICA: HOW FAR HAVE WE COME?

Global and Regional Focus Update of Global and Regional Initiatives – State of the Art of HTA&EE Regional Experiences as Learning and Inspirational Cases
MODERATOR
Federico Augustovski, MD, MS, PhD, Director, Economic Evaluations and HTA Department, Institute for Clinical Effectiveness and Health Policy (IECS), Professor of Public Health, University of Buenos Aires, and Staff Physician, Family and Community Medicine Division, Italian Hospital of Buenos Aires, Buenos Aires, Argentina

From globalization to regionalization of health technology assessment and health economic evaluations: an overview of global institutions of HTA/HEE (ISPOR, HTAi, INAHTA, WHO) and regional initiatives (EUNEHTA, HTAsia link network, ISPOR Consortia)
Andrés Pichon-Riviere, MD, MSc, PhD, Executive Director & Director of Health Technology Assessment & Economic Evaluations Department, Institute for Clinical Effectiveness and Health Policy (IECS), Vice-Chair, International Network of Agencies for Health Technology Assessment (INAHTA), Member of the Board of Directors, Health Technology Assessment International (HTAi), and Public Health Professor, University of Buenos Aires, Buenos Aires, Argentina

The International HTA Network for the Americas (REDETSA): gathering health technology assessment agencies and institutions in the Americas to advance different aspects and functions of HTA. Current climate
Alexandre Lemgruber, MSc, Regional Advisor, Health Technologies, Pan American Health Organization, Washington DC, USA

Global health and prioritization of evidence-based health policies informed by health technology assessment and economic evaluations
Jon Andrus, MD, Deputy Director, Pan American Health Organization/World Health Organization (PAHO/WHO), Washington, DC, USA

The right to health and health priorities: the national Constitutional mandate of the right to health and its consequential impact on health care budgets, efficiency, and equity
Leonardo Cubillos, MD, MPH, Senior Health Specialist, World Bank Institute (WBI), Washington DC, USA

SECOND PLENARY SESSION:
HTA as a Tool to Inform Pricing and Coverage Policies in the National Context: Case Studies from Argentina, Brazil, Chile, Colombia, Mexico, and Uruguay

Case Studies from Argentina
Jaime Lazovski, MD, PhD, MPH, MSc Health Policy, Undersecretary of Health Relations and Research, Ministry of Health of Argentina, Director, National Administration of Health Institutions and Laboratories, and Director General, Journal of Public Health of Argentina, Buenos Aires, Argentina

Case Studies from Brazil
Clarice Petramale, MD, Director, Department of Management and Incorporation of Health Technologies (DGITS), Secretariat of Science, Technology, and Strategic Inputs (SCTIE), Ministry of Health, Brasilia, Brazil

Case Studies from Chile
Marianela Castillo Riquelme, MSc, Health Economics Consultant & Technical Coordinator, Department of Health Economics, National Commission on Health Technology Assessment, Ministry of Health, Santiago, Chile

Case Studies from Colombia
Hector Eduardo Castro Jaramillo, MD, MSc, Executive Director, Institute for Health Technology Assessment (IETS - Instituto de Evaluación Tecnológica en Salud), Bogotá, Colombia

Case Studies from Mexico
Eduardo González-Pier, PhD, Executive President , Mexican Health Foundation (FUNSALUD), former Director of Finance, Mexican Institute for Social Security (IMSS), Mexico City, Mexico

Case Studies from Uruguay
Alarico Rodríguez, MD, Medical Technical Director, Uruguayan National Agency for Highly Specialized Medical Procedures (FNR – Fondo Nacional de Recursos), Montevideo, Uruguay

PODIUM AND POSTER PRESENTATIONS

For contributed research podium and poster abstracts and released slide or poster presentations for the ISPOR 4th Latin America Conference, see: ISPOR Scientific Presentations Database an electronic database of over 23,500 research papers presented at ISPOR Annual International Meetings, ISPOR Annual European Congresses, and biennial ISPOR Asia-Pacific & Latin America Conferences from 1998 to date.

  • ISPOR Scientific Presentations Database: http://www.ispor.org/research_study_digest/research_index.asp
  • Under Meeting select 4th Latin America Conference – Buenos Aires, Argentina
  • Select Search for all research podium and poster abstracts and available slide or poster presentations from the meeting. Alternatively search by disease/disorder, topic or subtopic.
 WORKSHOP PRESENTATIONS

(Presentations to be added pending speaker approval)

W1: ADAPTING GLOBAL PHARMACOECONOMIC MODELS TO THE LATIN AMERICAN CONTEXT - KEY CHALLENGES AND CONSIDERATIONS

Michael Drummond, PhD, Professor of Health Economics; Principal and Consultant, OptumInsight, Centre for Health Economics, University of York, Heslington, York, UK; Ximena Burbano-Levy, MD, International Research Director, Zilonis Health, Inc., Boca Raton, FL, USA; Jennifer Haig, BSc, Research Analyst, Product Value Strategy Consulting, Optum, Burlington, ON, Canada

W2: HOW TO HANDLE THE LACK OF INFORMATION IN EMERGING MARKETS. A LIST OF OPPORTUNITIES FROM LATIN AMERICA

How to handle the lack of information in emerging markets. A list of opportunities from Latin America
Rosina Hinojosa, MSc, Access Manager, Pfizer Inc., Lima, Peru
How to handle the lack of information in Emerging Markets A list of opportunities from Latin America
Gerardo Machnicki, MSc, PhD, Director, Global HE&OR, Novartis Latin America & Canada, Buenos Aires, Argentina

W3: ESQUEMAS DE PRECIOS Y REEMBOLSOS: LA POLÍTICA DE PRECIOS BASADA EN EL VALOR: ¿ES VIABLE EN LOS PAÍSES DE LATINOAMÉRICA?

Esquemas de tarificaciÓn y reembolsos: ¿La polÍtica de tarificaciÓn de precios basados en valor es factible en paÍses de Latinoamerica?
Manuel Antonio Espinoza, MD, MSc, PhD, Health Economist, Department of Public Health, Pontificia Universidad Católica de Chile, Santiago, Chile
PolÍticas de tarificaciÓn y reembolso.
Carla Castillo, MSc, Health Economist, Departamento de Metodologías, División de evaluación social de inversiones, Ministerio de Desarrollo Social, Santiago, Chile
PRICING AND REIMBURSEMENT SCHEMES: IS VALUE-BASED PRICING A FEASIBLE POLICY IN LATIN AMERICAN COUNTRIES?
Mark J. Sculpher, MSc, PhD, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, United Kingdom
HTA y PolÍticas de tarificaciÓn y reembolso
Nicolas Silva, MD, Academic, School of Public Health, Universidad de Chile, Santiago

W4: TOMA DE DECISIONES EN SALUD: UNA MIRADA DE INVESTIGADORES Y DECISORES DESDE EL INSTRUMENTO EVIDEM

Toma de Decisiones en Salud
Clarice Petramale, PhD, Director, Department of Health Technology Management and Incorporation, Brazilian Ministry of Health, Brasilia, Brazil;
Evaluación de resultados en la aplicación de políticas públicas sanitarias, un acercamiento al enfoque EVIDEM
Vega Sandoval, PhD, Encargado Sistema Control de Gestion Intendencia de Prestadores, Superintendencia de Salud, Santiago, Chile

W5: COMO MEDIR UTILIDADE E ENVOLVER O PÚBLICO NO PROCESSO DE AVALIAÇÃO DE TECNOLOGIAS DE SAÚDE

Instrumentos para aferir qualidade de vida
Monica A de C T Cintra, MD, MSc, Resarcher, Brazilian Ministry Of Health, Rio de Janeiro, Brazil
Como medir utilidade e envolver o público no processo de Avaliação de Tecnologias de Saúde (ATS)
Aline Silveira Silva, MSc, Consultant, Brazilian Ministry of Health, Brasilia, Brazil
Custo-utilidade e a Tomada de DecisÃo
Marisa S Santos, Doutora, Médica, Coordenadora, NATS, INC, Rio de Janeiro, Brazil

W7: ISPOR-SMDM GUIDELINES FOR GOOD MODELING PRACTICES

Las GuÍas ISPOR-SMDM de buenas prÁcticas en modelaciÓn
J. Jaime Caro, MDCM, FRCPC, FACP, Profesor en Medicina y Epidemiologia y Bioestadistica, McGill, Montreal, QC, Canada; Andrew Briggs, DPhil, MSc, William R. Lindsay President of Health Economics, Department of Health Economics & Health Technology Assessment, Institute of Health & Wellbeing, University of Glasgow, Glasgow, UK; Karen Kuntz, ScD, Professor, School of Public Health, University of Minnesota, Minneapolis, MS, USA; Uwe Siebert, MD, MPH, MSc, ScD, Professor, Department of Public Health and Health Technology Assessment, UMIT / Oncotyrol / Harvard University, Hall i.T., Innsbruck, Austria

W8: USING EVIDENCE ELICITED FROM EXPERTS IN DECISION MAKING

UTILIZANDO EVIDENCIA OBTENIDA DESDE EXPERTOS EN TOMA DE DECISIONES
Manuel Antonio Espinoza, MD, PhD, Académico, Departamento de Salud Pública, Pontificia Universidad Católica de Chile, Santiago, Chile
USING EVIDENCE ELICITED FROM EXPERTS IN DECISION MAKING: Case study – NPWT for pressure ulcers
Pedro Saramago, PhD, Research Fellow, Centre for Health Economics, University of York, York, UK
USING EVIDENCE ELICITED FROM EXPERTS IN DECISION MAKING
Mark J. Sculpher, MSc, PhD, Professor of Health Economics, Centre for Health Economics, University of York, York, UK

W9: HOW AND WHY MARKETS IN LATIN AMERICA NEED TO HAVE THEIR OWN COST EFFECTIVENESS THRESHOLDS

HOW AND WHY MARKETS IN LATIN AMERICA NEED TO HAVE THEIR OWN COST EFFECTIVENESS THRESHOLDS
Otávio Augusto Camara Clark, MD, PhD, Director, Evidencias, Campinas, Brazil

W10: SUCCESSFUL REAL WORLD DATA GENERATION AND USE IN LATIN AMERICA: EXPLORING THE POLICY PRINCIPLES, OPERATIONAL FRAMEWORK AND ANALYTIC CONSIDERATIONS

HOW AND WHY MARKETS IN LATIN AMERICA NEED TO HAVE THEIR OWN COST EFFECTIVENESS THRESHOLDS: Policy principles, operational framework and analytic considerations
Gerardo Machnicki, MSc, PhD, Director, Global HE&OR, Novartis Latin America & Canada, Buenos Aires, Argentina

W11: METANALISIS DE COMPARACIONES INDIRECTAS: Y SI NO HAY COMPARACIONES CABEZA A CABEZA?

METANALISIS DE COMPARACIONES INDIRECTAS: Y SI NO HAY COMPARACIONES CABEZA A CABEZA?
Sebastián García Martí, MD, MSc, Coordinator, Health Technology Assessment Department, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina; Agustín Ciapponi, MD, MSc, Coordinator, Southern American Branch of the Iberoamerican Cochrane Centre, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Buenos Aires, Argentina

W13: TRANSFERABILITY OF COST-EFFECTIVENESS ANALYSIS: REQUIREMENTS TO IMPROVE DECISION-MAKING IN LATIN AMERICA

TRANSFERABILITY OF COST-EFFECTIVENESS ANALYSIS: REQUIREMENTS TO IMPROVE DECISION MAKING IN LATIN AMERICA
Federico Augustovski, MD, MSc, PhD
, Director, Economic Evaluations & HTA Department, Institute for Clinical Effectiveness and Health Policy (IECS), and Professor of Public Health, University of Buenos Aires, Buenos Aires, Argentina
Transferability of health economic information: Models or Trials?
Andrew Briggs, DPhil, MSc, William R. Lindsay President of Health Economics, Department of Health Economics & Health Technology Assessment, Institute of Health & Wellbeing, University of Glasgow, Glasgow, UK
Transferability of Cost-Effectiveness Analysis: Requirements to improve decision making in Latin America
Manuel Antonio Espinoza, MD, MSc, PhD, Health Economist, Department of Public Health, Pontificia Universidad Católica de Chile, Santiago, Chile
TRANSFERABILITY OF COST-EFFECTIVENESS ANALYSIS: REQUIREMENTS TO IMPROVE DECISION MAKING IN LATIN AMERICA
Mark J. Sculpher, MSc, PhD, Professor, Centre for Health Economics, University of York, Heslington, York, UK
 
ISSUE PANEL PRESENTATIONS

(Presentations to be added pending speaker approval)

IP1: EVALUACIÓN ECONÓMICA EN LATINOAMÉRICA: ¿EL ANÁLISIS DE COSTO-EFECTIVIDAD RESPONDE NUESTRAS NECESIDADES?

EvaluaciÓn econÓmica en LatinoamÉrica: ¿el anÁlisis de costo-efectividad responde nuestras necesidades?
Federico Augustovski, MD, MSc, PhD, Director, Economic Evaluations & HTA Department, Institute for Clinical Effectiveness and Health Policy (IECS), and Professor of Public Health, University of Buenos Aires, Buenos Aires, Argentina

LA TESIS QUE PRESENTO ES QUE EL MÉTODO DE COSTO EFECTIVIDAD ES LIMITADO PARA AYUDAR EN LA TOMA DE DECISIONES EN UNA INSTITUCIÓN PUBLICA DEL SALUD
Guillermo Melendez, MD, MSc
, Consultant, Fundación Mexicana para la Salud AC, Mexico D.F., Mexico
EVALUACION ECONOMICA EN LATINOAMERICA: ¿EL ANALISIS DE COSTO-EFECTIVIDAD RESPONDE NUESTRAS NECESIDADES?
Manuel Antonio Espinoza, MD, MSc, PhD
, Health Economist, Department of Public Health, Pontificia Universidad Católica de Chile, Santiago, Chile

IP2: COST EFFECTIVENESS OF MRI IN THE EARLY DETECTION OF BREAST CANCER RECURRENCE IN PATIENTS UNDERGOING TREATMENT WITH CONSERVATIVE SURGERY: IS IT FEASIBLE IN LATIN AMERICA?

The cost-effectiveness of breast magnetic resonance imaging (MRI) to detect a locoregional recurrence in patients with breast conserving therapy. Is it feasible in Latin America?
Elide Sbardellotto Mariano da Costa, MD
, Cardio Audit, Curitiba City Health Institute, Curitiba, Brazil; Adriano Hyeda, MD, Audit, Santa Casa De Misericordia Hospital, Curitiba, Paraná, Brazil; Elio Tanaka, MD, Oncologist, Health Economics Researcher and Head, Audit Department, Curitiba City Health Institute, Curitiba, Brazil

IP4: APLICACIÓN DE LA EVIDENCIA DE COSTO-EFECTIVIDAD Y COSTO-UTILIDAD A LOS PROCESOS DE TOMA DE DECISIÓN SOBRE PRECIO Y COBERTURA DE NUEVOS MEDICAMENTOS. ¿EXISTE UN UMBRAL DE COSTO-EFECTIVIDAD EN LATINOAMÉRICA?

APLICACIÓN DE LA EVIDENCIA DE COSTO-EFECTIVIDAD Y COSTO-UTILIDAD A LOS PROCESOS DE TOMA DE DECISIÓN SOBRE PRECIO Y COBERTURA DE NUEVOS MEDICAMENTOS. ¿EXISTE UN UMBRAL DE COSTO-EFECTIVIDAD EN LATINOAMÉRICA?
Marianela Castillo, MSc
, Economista de la Salud, Ministerio de Salud de Chile, Santiago, Región Metropoli, Chile

¿EXISTE UN UMBRAL DE COSTO-EFECTIVIDAD EN LATINOAMÉRICA?
Clarice Petramale, PhD, Director, Department of Health Technology Management and Incorporation, Brazilian Ministry of Health, Brasilia, Brazil

AplicaciÓn de la evidencia de costo-efectividad y costo-utilidad a los procesos de toma de decisiÓn sobre precio y cobertura de nuevos medicamentos. ¿Existe un umbral de costo-efectividad en LatinoamÉrica?
Andrés Pichon Riviere, MD MSc PhD, Director of HTA and HEE, (IECS) Institute for Clinical Effectiveness and Health Policy, Buenos Aires, Argentina

IP6: ARE LOCAL QUALITY OF LIFE DATA NEEDED TO GUIDE REIMBURSEMENT DECISIONS IN LATIN AMERICA?

ARE LOCAL QUALITY OF LIFE DATA NEEDED TO GUIDE REIMBURSEMENT DECISIONS IN LATIN AMERICA?
Andrew J Lloyd, DPhil
, Vice President, Patient Reported Outcomes, Oxford Outcomes Ltd., an ICON PLC Company, Oxford, Oxon, UK; Federico Augustovski, MD, MSc, PhD, Director, Economic Evaluations & HTA Department, Institute for Clinical Effectiveness and Health Policy (IECS), and Professor of Public Health, University of Buenos Aires, Buenos Aires, Argentina; Pedro Rizo Ríos, MD, Director General Adjunto de Priorización, Consejo de Salubridad General, Mexico D.F., Mexico; Vijayveer Bonthapally, PhD, Health Economics and Outcomes Research, Millennium Pharmaceuticals Inc, Cambridge, MA, USA

IP7: ACCESS TO INNOVATIVE MEDICINES IN LATIN AMERICA – WHAT IS THE SOLUTION?

ACCESS TO INNOVATIVE MEDICINES IN LATIN AMERICA – WHAT IS THE SOLUTION?
Michelle L Sotak, MPH, MBA
, Associate Director, Product Value Strategy, Optum, Chicago, IL, USA; Otávio Augusto Camara Clark, MD, PhD, Director, Evidencias, Campinas, Brazil; Roberto Bitton, MD, Professor, Center of Multidisciplinary Studies in Health Economics and Management, Austral University, Vicente López, Argentina; Leon Zapata, QF, Director, Guia Mark, S. A. de C. V., Mexico, D.F., Mexico
ACCESS TO INNOVATIVE MEDICINES IN LATIN AMERICA – WHAT IS THE SOLUTION?
Otávio Augusto Camara Clark, MD, PhD
, Director, Evidencias, Campinas, Brazil

IP9: ACCESO AL MERCADO POR VIA JUDICIAL; NECESIDAD O AMENAZA?

ACCESO AL MERCADO POR VÍA JUDICIAL ¿NECESIDAD O AMENAZA?
Roberto Iunes, PhD
, Economista Senior en Salud, Instituto del Banco Mundial, Washington, DC, USA
ACCESO MERCADO POR VÍA JUDICIAL ¿NECESIDAD O AMENAZA?
J. Jaime Caro, MDCM, FRCPC, FACP
, Vicepresidente Principal, Investigación, Evidera, Lexington, MA, EUA y Profesor Adjunto de Medicina, Profesor Adjunto de Epidemiología y Bioestadística, Universidad McGill, Montreal QC, Canadá; Rodrigo Salinas, MD, Profesor Asistente, Facultad de Medicina, Universidad de Chile, Santiago, Chile; Román Navarro, LLM, Miembro de la Comisión de Derecho de la Salud, del Colegio de Abogados de Costa Rica, San Jose, Costa Rica
ISPOR FORUMS

ISPOR CHILE REGIONAL CHAPTER FORUM

CHALLENGES FOR THE IMPLEMENTATION OF AN ETESA SYSTEM IN CHILE: POLITICAL TENSIONS BETWEEN PLAYERS AND THE POSSIBILITIES OF CONSTRUCTING AN AGENDA
Rony Lenz Alcayaga, MA, Professor, School of Public Health, UCH, Santiago, Chile

EDUCATIONAL SYMPOSIA

(Presentations to be added pending symposia host approval)

MANAGING DIABETES IN LATIN AMERICA – THE ROLE OF INNOVATIVE MEDICINES
(Sponsored by Eli Lilly and Company)

Control de la Diabetes en America Latina - El Rol de los Medicamentos Innovadores
Manny Papadimitropoulos, PhD, Director, Health Outcomes, Emerging Markets, Eli Lilly & Company and Assistant Professor, Faculty of Pharmacy, University of Toronto, Toronto, Canada; Juan Jose Gagliardino, MD, PhD, Director, Center of Experimental and Applied Endocrinology (CENEXA), La Plata University (UNLP)-CONICET, PAHO/WHO Associated Center, La Plata, Buenos Aires, Argentina; Armando Arredondo, MD, PhD, Senior Researcher, National Institute of Public Health, Cuernavaca, Morelos, Mexico; Joao Paulo Reis Neto, MD, Executive Coordinator of Technology Implementation Group, CAPESESP, Rio de Janeiro, Brazil

THE ROLE OF MULTI-CRITERIA DECISION ANALYSIS (MCDA) IN HEALTH TECHNOLOGY ASSESSMENT (HTA) AND REIMBURSEMENT DECISION MAKING IN LATIN AMERICA
(Sponsored by Amgen)

MCDA concepts and application in decision making
Mireille M. Goetghebeur, PhD, President, The EVIDEM™ Collaboration and Professor, Department of Health Administration, University of Montreal, Montreal, QC, Canada

MCDA Utilization for Public Health Decision Process
Mondher Toumi, MD, MSc, PhD, Chair of Market Access, Universite Claude Bernard, Lyon, France

FROM INCREMENTAL COST-EFFECTIVENESS RATIO TO INCREMENTAL COST-EFFECTIVENESS RANGE: ADJUSTING THE THRESHOLD FOR LATIN AMERICAN COUNTRIES
(Sponsored by Pfizer)

DOES A SINGLE COST-EFFECTIVENESS THRESHOLD MAKE SENSE?
Federico Augustovski, MD, MSc, PhD, Director, Economic Evaluations and HTA Department (IECS) and Professor of Public Health, University of Buenos Aires, Buenos Aires, Argentina

ABANDONING A SINGLE THRESHOLD: A CASE STUDY OF BRAZIL
Gabriela Tannus Branco de Araújo, MSc, MBA, Owner & Health Economics Director, Axia.Bio Consulting, São Paulo, Brazil

CHALLENGES WITH IMPLEMENTING DECISIONS USING ICER THRESHOLDS
Iris Contreras-Hernández, MD, Clinical Researcher, Mexican Institute of Social Security, Mexico City, Mexico

WORKING WITH HEALTH TECHNOLOGY ASSESSMENT (HTA) IN LATIN AMERICA: CHALLENGES AND OPPORTUNITIES
(Sponsored by Double Helix Consulting)

HTA IN BRAZIL – CURRENT AND FUTURE TRENDS
Flávia Tavares Silva Elias, PhD, MBA, Researcher, FIOCRUZ (Oswaldo Cruz Foundation, Ministry of Health

ROLE OF HTA IN ARGENTINA: FACTORS AFFECTING HTA DECISIONS AND DRUG ACCESS
Joaquín E. Caporale, MGE, Health Economics Coordinator, Institute for Clinical Effectiveness & Health Policy (IECS), Buenos Aires, Argentina

IN LATIN AMERICA, SHOULD WE ASSESS VALUE OR USE REFERENCE PRICING? BOTH OR NEITHER?
(Sponsored by Merck Sharp & Dohme)

Gastos en Salud: Buscando la Eficiencia
Rafael Alfonso, MD, MSc, PhD, Scientific Director, Surgical Outcomes Research Center – SORCE, Department of Surgery, University of Washington, Seattle, WA, USA

LATIN AMERICA: HEALTH TECHNOLOGY ASSESSMENT VS. INTERNATIONAL REFERENCE PRICING
Monica Martin de Bustamante, AB, BE, Managing Director, CB Partners, New York, NY, USA

 

Contact ISPOR @ info@ispor.org | View Legal Disclaimer
© 2018 International Society for Pharmacoeconomics and Outcomes Research.
All rights reserved under International and Pan-American Copyright Conventions.